Winthrop Advisory Group LLC Grows Stock Position in Merck & Co., Inc. (NYSE:MRK)

Winthrop Advisory Group LLC raised its holdings in Merck & Co., Inc. (NYSE:MRK) by 3.9% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 6,052 shares of the company’s stock after buying an additional 226 shares during the quarter. Winthrop Advisory Group LLC’s holdings in Merck & Co., Inc. were worth $458,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in MRK. Amundi purchased a new stake in Merck & Co., Inc. in the second quarter valued at about $784,989,000. Barrow Hanley Mewhinney & Strauss LLC raised its stake in Merck & Co., Inc. by 1,324.3% in the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 10,145,652 shares of the company’s stock valued at $789,028,000 after buying an additional 9,433,323 shares during the last quarter. LSV Asset Management increased its holdings in shares of Merck & Co., Inc. by 47.8% in the second quarter. LSV Asset Management now owns 14,306,091 shares of the company’s stock valued at $1,112,584,000 after purchasing an additional 4,628,832 shares during the period. FMR LLC increased its holdings in shares of Merck & Co., Inc. by 67.3% in the second quarter. FMR LLC now owns 10,357,873 shares of the company’s stock valued at $805,532,000 after purchasing an additional 4,165,565 shares during the period. Finally, Morgan Stanley increased its holdings in shares of Merck & Co., Inc. by 17.1% in the second quarter. Morgan Stanley now owns 26,289,496 shares of the company’s stock valued at $2,044,534,000 after purchasing an additional 3,832,086 shares during the period. Institutional investors own 71.79% of the company’s stock.

In other news, insider Kenneth C. Frazier sold 663,881 shares of the firm’s stock in a transaction that occurred on Tuesday, November 9th. The stock was sold at an average price of $82.26, for a total value of $54,610,851.06. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Sanat Chattopadhyay sold 24,619 shares of Merck & Co., Inc. stock in a transaction that occurred on Friday, October 29th. The stock was sold at an average price of $87.32, for a total value of $2,149,731.08. The disclosure for this sale can be found here. Insiders have sold 936,784 shares of company stock worth $78,682,559 in the last quarter. 0.32% of the stock is currently owned by company insiders.

A number of research analysts have recently weighed in on the company. Truist increased their price objective on Merck & Co., Inc. from $92.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday. Berenberg Bank reissued a “hold” rating and issued a $92.00 price objective (up from $86.00) on shares of Merck & Co., Inc. in a report on Sunday, October 10th. Mizuho assumed coverage on Merck & Co., Inc. in a report on Thursday, October 28th. They issued a “buy” rating and a $99.00 price objective on the stock. Truist Securities increased their price objective on Merck & Co., Inc. from $92.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Argus raised Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $110.00 price objective on the stock in a report on Monday, November 1st. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $95.73.

Merck & Co., Inc. stock traded down $0.52 during midday trading on Thursday, hitting $82.28. 8,534,741 shares of the company were exchanged, compared to its average volume of 12,415,974. The firm has a market capitalization of $207.83 billion, a PE ratio of 29.07, a price-to-earnings-growth ratio of 2.11 and a beta of 0.46. Merck & Co., Inc. has a fifty-two week low of $70.89 and a fifty-two week high of $91.40. The business has a fifty day simple moving average of $80.47 and a two-hundred day simple moving average of $78.04. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.07 and a current ratio of 1.31.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Wednesday, October 27th. The company reported $1.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.55 by $0.20. The company had revenue of $13.15 billion for the quarter, compared to the consensus estimate of $12.32 billion. Merck & Co., Inc. had a return on equity of 48.21% and a net margin of 14.64%. Merck & Co., Inc.’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.74 earnings per share. As a group, equities analysts expect that Merck & Co., Inc. will post 5.76 earnings per share for the current year.

Merck & Co., Inc. Company Profile

Merck & Co, Inc engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

See Also: What is the NASDAQ Stock Market?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.